Overview

This is a prospective, single-arm, open-label and dose-escalation Investigator Initialed study to evaluate LUCAR-G79 in adult subjects with relapsed/refractory autoimmune diseases.

Eligibility

Inclusion Criteria:

1. Subjects voluntary agreement to provide written informed consent.
2. Aged 18 to 70 years, either sex.
3. Adequate organ function meet screening criteria.
4. Positive test for cluster of differentiation antigen 19 (CD19).

   SLE

   • Have been diagnosed of SLE at least 6 months before screening.
   • At screening, antinuclear antibody, and/or anti-dsDNA antibody, and/or anti-Smith antibody should be positive.
   • Fulfill relapsed/refractory SLE conditions.

   SSc

   • Have been diagnosed of SSc before screening.
   • At screening, mRSS is higher than 10.
   • Fulfill relapsed/refractory SSc conditions.

   AAV

   • Have been diagnosed of AAV before screening.
   • Antineutrophil Cytoplasmic Antibody (ANCA)-related antibodies meet one of the following conditions: a. Positive for anti-myeloperoxidase (MPO) and/or p-ANCA; b. Positive for anti-proteinase 3 (PR3) and/or c-ANCA.
   • Fulfill relapsed/refractory AAV conditions.

   IIM

   • Have been diagnosed of IIM before screening.
   • Positive test for myositis-associated antibodies or myositis-specific antibodies at screening.
   • Fulfill relapsed/refractory IIM conditions.

   TAK

   • Have been diagnosed of TAK before screening.
   • Active TAK patients meet screening criteria.
   • Fulfill relapsed/refractory TAK conditions.

IgG4-RD:

• Have been diagnosed of IgG4-RD before screening.
• Active IgG4-RD patients meet screening criteria.
• Fulfill relapsed/refractory IgG4-RD conditions.

Exclusion Criteria:

1. Active infections such as hepatitis and tuberculosis.
2. Other autoimmune diseases.
3. Serious underlying diseases such as tumor, uncontrolled diabetes.
4. Female subjects who were pregnant, breastfeeding.
5. Those with a history of major organ transplantation.